TY - JOUR
AU - Zhang, Peng
AU - Zhu, Lihua
AU - Cai, Jingjing
AU - Lei, Fang
AU - Qin, Juan-Juan
AU - Xie, Jing
AU - Liu, Ye-Mao
AU - Zhao, Yan-Ci
AU - Huang, Xuewei
AU - Lin, Lijin
AU - Xia, Meng
AU - Chen, Ming-Ming
AU - Cheng, Xu
AU - Zhang, Xiao
AU - Guo, Deliang
AU - Peng, Yuanyuan
AU - Ji, Yan-Xiao
AU - Chen, Jing
AU - She, Zhi-Gang
AU - Wang, Yibin
AU - Xu, Qingbo
AU - Tan, Renfu
AU - Wang, Haitao
AU - Lin, Jun
AU - Luo, Pengcheng
AU - Fu, Shouzhi
AU - Cai, Hongbin
AU - Ye, Ping
AU - Xiao, Bing
AU - Mao, Weiming
AU - Liu, Liming
AU - Yan, Youqin
AU - Liu, Mingyu
AU - Chen, Manhua
AU - Zhang, Xiao-Jing
AU - Wang, Xinghuan
AU - Touyz, Rhian M.
AU - Xia, Jiahong
AU - Zhang, Bing-Hong
AU - Huang, Xiaodong
AU - Yuan, Yufeng
AU - Rohit, Loomba
AU - Liu, Peter P.
AU - Li, Hongliang
PY - 2020
DA - June
TI - Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19
JO - Circulation Research
EP - 1681
VL - 126
IS - 12
DO - http://dx.doi.org/10.1161/circresaha.120.317134
AB - Rationale: Use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) is a major concern for clinicians treating coronavirus disease 2019 (COVID-19) in patients with hypertension. Objective: To determine the association between in-hospital use of ACEI/ARB and all-cause mortality in COVID-19 patients with hypertension. Methods and Results: This retrospective, multi-center study included 1128 adult patients with hypertension diagnosed with COVID-19, including 188 taking ACEI/ARB (ACEI/ARB group; median age 64 [IQR 55-68] years; 53.2% men) and 940 without using ACEI/ARB (non-ACEI/ARB group; median age 64 [IQR 57-69]; 53.5% men), who were admitted to nine hospitals in Hubei Province, China from December 31, 2019 to February 20, 2020. Unadjusted mortality rate was lower in the ACEI/ARB group versus the non-ACEI/ARB group (3.7% vs. 9.8%; P = 0.01). In mixed-effect Cox model treating site as a random effect, after adjusting for age, gender, comorbidities, and in-hospital medications, the detected risk for all-cause mortality was lower in the ACEI/ARB group versus the non-ACEI/ARB group (adjusted HR, 0.42; 95% CI, 0.19-0.92; P =0.03). In a propensity score-matched analysis followed by adjusting imbalanced variables in mixed-effect Cox model, the results consistently demonstrated lower risk of COVID-19 mortality in patients who received ACEI/ARB versus those who did not receive ACEI/ARB (adjusted HR, 0.37; 95% CI, 0.15-0.89; P = 0.03). Further subgroup propensity score-matched analysis indicated that, compared to use of other antihypertensive drugs, ACEI/ARB was also associated with decreased mortality (adjusted HR, 0.30; 95%CI, 0.12-0.70; P = 0.01) in COVID-19 patients with hypertension. Conclusions: Among hospitalized COVID-19 patients with hypertension, inpatient use of ACEI/ARB was associated with lower risk of all-cause mortality compared with ACEI/ARB non-users. While study interpretation needs to consider the potential for residual confounders, it is unlikely that in-hospital use of ACEI/ARB was associated with an increased mortality risk.
PB - American Heart Association
UR - http://eprints.gla.ac.uk/214771/
KW - Coronavirus (COVID-19)
ER